Search results for " eosinophils"

showing 9 items of 19 documents

The Role of Transforming Growth Factor-β1 in Airway Inflammation of Childhood Asthma

2013

TGF-beta-targeting structural and inflammatory cells has been implicated in the mechanisms leading to the inflammatory and restructuring processes in asthma, suggesting an impact of TGF-beta1 signaling on the development and persistency of this disease. We investigated the potential early involvement of TGF-beta1 activity in the immunological and molecular mechanisms underlying progression of inflammation in childhood asthma. We evaluated the levels of TGF-beta1 in induced sputum supernatants (ISSs) and the expression of small mother cell against decapentaplegic (Smad) 2 and Smad7 proteins in induced sputum cells (ISCs) from children with intermittent asthma (IA), moderate asthma (MA) and c…

MaleNeutrophilsSmad2 ProteinSMADEosinophilAdrenal Cortex HormoneSeverity of Illness IndexAdrenal Cortex HormonesImmunology and AllergyAge FactorPhosphorylationChildLungNeutrophilAge FactorsBronchodilator Agentsmedicine.anatomical_structureFemalemedicine.symptomCase-Control StudieHumanSignal TransductionGranulocyte activationAdolescentImmunologyAge Factors; Humans; Child; Macrophage-1 Antigen; Adrenal Cortex Hormones; Granulocytes; Neutrophils; Phosphorylation; Eosinophils; Adolescent; Signal Transduction; Male; Severity of Illness Index; Respiratory Mucosa; Asthma; Transforming Growth Factor beta1; Epithelial Cells; Lung; Smad2 Protein; Case-Control Studies; Smad7 Protein; Sputum; Administration Inhalation; Bronchodilator Agents; Cell Line; Female; Cell AdhesionMacrophage-1 AntigenCD18InflammationRespiratory MucosaGranulocyteCell LineSmad7 ProteinTransforming Growth Factor beta1Administration InhalationCell AdhesionmedicineHumansCell adhesionBronchodilator AgentPharmacologyEpithelial Cellbusiness.industrySputumGranulocyteEpithelial CellsEosinophilAsthmaEosinophilsCase-Control StudiesImmunologySputumbusinessGranulocytesInternational Journal of Immunopathology and Pharmacology
researchProduct

Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial

2017

<b><i>Background:</i></b> Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. <b><i>Methods:</i></b> In this 21-day,<b> </b>open-label, randomized controlled study, 36 SAR children (aged 6-13 years) with a Total 5 Symptom Score (T5SS) ≥5 received twice-daily BHS or NSS…

MaleNeutrophilsmedicine.medical_treatmentSodium ChlorideGastroenterologylaw.inventionPittsburgh Sleep Quality IndexLeukocyte Count0302 clinical medicineQuality of lifeRandomized controlled triallawSurveys and QuestionnairesBuffered hypertonic solutionImmunology and AllergyChild030223 otorhinolaryngologyChildrenSalineHypertonicRhinitisNasal symptomGeneral MedicineNasal irrigationTreatment OutcomeNasal cytologyFemaleSaline SolutionNasal symptomsQuality of lifemedicine.medical_specialtyAdolescentSeasonal allergic rhinitisImmunology03 medical and health sciencesAllergicBuffered hypertonic solution; Children; Nasal cytology; Nasal symptoms; Quality of life; Seasonal allergic rhinitis; Adolescent; Child; Eosinophils; Female; Humans; Leukocyte Count; Male; Nasal Lavage; Neutrophils; Quality of Life; Rhinitis Allergic Seasonal; Saline Solution Hypertonic; Sodium Chloride; Surveys and Questionnaires; Treatment Outcome; Immunology and Allergy; ImmunologyInternal medicinemedicineHumansSaline Solution HypertonicSeasonalbusiness.industryRhinitis Allergic SeasonalNasal symptomsHypertonic salineEosinophils030228 respiratory systemNasal cytologyImmunologyNasal LavagebusinessInternational Archives of Allergy and Immunology
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

Effect of age and asthma duration upon elastase and alpha1-antitrypsin levels in adult asthmatics

2003

In asthmatic subjects an imbalance between elastase and alpha1-antitrypsin (alpha1-PI) exists. This study aims to evaluate whether ageing per se affects the levels of elastase. Both young and elderly asthmatics with comparable severity and duration of disease, as well as young and elderly healthy subjects, underwent an induced sputum procedure to measure levels of elastase and alpha1-PI. The percentage of sputum neutrophils and eosinophils was higher in young and elderly asthmatics than in young and elderly controls. The levels of both total and active elastase were significantly higher in young and elderly asthmatics than in young and elderly controls, and directly correlated with the perc…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtySputum CytologyPathologyAgingNeutrophilsDiseaseEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyLeukocyte CountInternal medicineForced Expiratory VolumeMedicineHumansAsthmaAgedPancreatic Elastasebusiness.industryRespiratory diseaseElastaseNeutrophilSputumsocial sciencesMiddle Agedmedicine.diseasehumanitiesPathophysiologyAsthmaEosinophilsAgeingalpha 1-AntitrypsinAdult; Aged; Aging; Asthma; Eosinophils; Forced Expiratory Volume; Humans; Leukocyte Count; Middle Aged; Neutrophils; Pancreatic Elastase; Sputum; alpha 1-AntitrypsinSputummedicine.symptombusinessHuman
researchProduct

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

2019

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The severity grading systems proposed by the Global initiative for Chronic Obstructive Lung Disease (GOLD) have changed over time. The aim of the study was to evaluate if the different GOLD classifications can capture the complexity of the disease by investigating the distribution of lung function and clinical parameters across the GOLD classification systems. This was an observational, retrospective, multicentre study. COPD patients were stratified according to the GOLD severity grading proposed in the 2007, and to the ABCD assessment tool present in the 2011, and 2017 versions of the initiative. Data from body plethy…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyphenotypeCopd patientsSettore MED/10 - Malattie dell'Apparato RespiratorioVital CapacitySocio-culturalePulmonary diseaseSeverity gradingDiseaseGOLD documentairflow obstructionurologic and male genital diseasesSeverity of Illness IndexPulmonary Disease03 medical and health sciencesLeukocyte CountPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineForced Expiratory VolumemedicineCOPDHumanseosinophil030212 general & internal medicineAgedRetrospective StudiesCOPDbusiness.industryairflow obstruction COPD eosinophil GOLD document phenotypeMiddle Agedmedicine.diseaseObstructive lung diseaserespiratory tract diseasesEosinophils030228 respiratory systemItalyairflow obstruction; COPD; eosinophil; GOLD document; phenotype; Aged; Eosinophils; Female; Forced Expiratory Volume; Humans; Inspiratory Capacity; Italy; Leukocyte Count; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Retrospective Studies; Risk Factors; Severity of Illness Index; Vital CapacityObservational studyFemalesense organsbusinessCOPD; GOLD document; airflow obstruction; eosinophil; phenotypeInspiratory CapacityCOPD
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

Taurine chloramine inhibits functional responses of human eosinophils in vitro

2009

10 páginas, 7 figuras, 1 tabla.

Taurinemedicine.medical_specialtyTaurineImmunologyApoptosisEosinophil peroxidasechemistry.chemical_compoundSuperoxidesInternal medicineTaurine-chloraminemedicineHumansImmunology and AllergyEnzyme InhibitorsSuperoxide anionCells CulturedPeroxidaseRespiratory BurstEosinophil cationic proteinbiologySuperoxideEosinophil Cationic ProteinZymosanNF-kappa BGranulocyte-Macrophage Colony-Stimulating FactorNADPH OxidasesEosinophilPhosphoproteinsMolecular biologyHuman eosinophilsLeukotriene C4Respiratory burstEosinophilsmedicine.anatomical_structureEndocrinologychemistryEicosanoidbiology.proteinCalciumEosinophil cationic proteinInterleukin-5Eosinophil peroxidase
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct